Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT01801046

Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This phase I trial studies the side effects of donor stem cell transplant in treating patients with high risk acute myeloid leukemia. Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect)

Status: 
Recruiting
Study Date: 
Fri, 03/01/2013 to Tue, 03/01/2016
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: mitoxantrone hydrochloride Given IV Other Names: CL 232315 DHAD DHAQ Novantrone Drug: cytarabine Given IV Other Names: ARA-C arabinofuranosylcytosine arabinosylcytosine Cytosar-U cytosine arabinoside Procedure: peripheral blood stem cell transplantation Undergo HMMACT with G-PBSC Other Names: PBPC transplantation PBSC transplantation peripheral blood progenitor cell transplantation transplantation, peripheral blood stem cell Other: laboratory biomarker analysis Correlative studies